Respiratory failure – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:13:56 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Respiratory failure – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Anticoagulation Strategies with Heparin, Enoxaparin, and Argatroban for Patients with Respiratory or Circulatory Failure on ECMO Support https://clinicaltrials.eu/trial/study-on-anticoagulation-strategies-with-heparin-enoxaparin-and-argatroban-for-patients-with-respiratory-or-circulatory-failure-on-ecmo-support/ Wed, 29 Apr 2026 15:02:30 +0000 https://clinicaltrials.eu/trial/study-on-anticoagulation-strategies-with-heparin-enoxaparin-and-argatroban-for-patients-with-respiratory-or-circulatory-failure-on-ecmo-support/ This clinical trial is focused on studying different treatment strategies for patients who need support from a machine called Extracorporeal Membrane Oxygenation, or ECMO. ECMO is used in serious conditions like Respiratory Insufficiency, Respiratory Failure, Circulatory Failure, and Acute Respiratory Distress Syndrome. The study will compare three medications that help prevent blood clots, which are a common risk during ECMO therapy. These medications are Unfractionated Heparin, Argatroban, and Low-molecular-weight Heparin (also known as Enoxaparin).

The purpose of the study is to see how these medications affect the occurrence of blood clots during ECMO therapy. Participants will be randomly assigned to receive one of the three medications. The study will monitor the incidence of blood clots, such as pulmonary embolism and deep vein thrombosis, as well as any bleeding events. The study will last for a period of up to six months for each participant.

Throughout the study, participants will receive regular check-ups to monitor their health and the effectiveness of the medication they are receiving. The goal is to determine which medication is most effective in preventing blood clots without causing significant bleeding. This information will help improve treatment strategies for patients requiring ECMO support in the future.

]]> Study on the Effects of Methylprednisolone and Isavuconazonium Sulfate in Immunocompromised Patients with Acute Respiratory Failure of Unknown Cause https://clinicaltrials.eu/trial/study-on-the-effects-of-methylprednisolone-and-isavuconazonium-sulfate-in-immunocompromised-patients-with-acute-respiratory-failure-of-unknown-cause/ Wed, 29 Apr 2026 15:01:38 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-methylprednisolone-and-isavuconazonium-sulfate-in-immunocompromised-patients-with-acute-respiratory-failure-of-unknown-cause/ This clinical trial is focused on studying treatments for patients who are immunocompromised and experiencing acute respiratory failure of unknown origin. Being immunocompromised means that a person’s immune system is weakened, which can happen due to conditions like cancer or after receiving an organ transplant. The study will explore the effects of using steroids and/or antifungal medications to help these patients. Specifically, the trial will use a steroid called METHYLPREDNISOLONE and an antifungal medication called CRESEMBA (also known as isavuconazonium sulfate).

The purpose of the study is to see if these treatments can reduce the risk of death within 90 days for patients with acute respiratory failure. Participants in the study will receive either the medications or a placebo, which is a substance with no active ingredients, for up to 14 days or until they are discharged from the intensive care unit (ICU). The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, researchers will monitor various outcomes, including survival rates at different time points, the occurrence of infections, and the overall quality of life of the participants. The goal is to gather information that could lead to better treatment strategies for immunocompromised patients facing severe respiratory issues.

]]> Study on the Effects of Iloprost Trometamol in Patients with Infectious Lung Disease on Mechanical Ventilation https://clinicaltrials.eu/trial/study-on-the-effects-of-iloprost-trometamol-in-patients-with-infectious-lung-disease-on-mechanical-ventilation/ Wed, 29 Apr 2026 14:30:44 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-iloprost-trometamol-in-patients-with-infectious-lung-disease-on-mechanical-ventilation/ This clinical trial is focused on studying a condition known as infectious pulmonary endotheliopathy, which affects the blood vessels in the lungs and can lead to severe breathing problems. The trial will explore the effects of a treatment using a medication called Ilomedin, which contains the active substance iloprost trometamol. This medication is given as a solution for infusion, meaning it is administered directly into the bloodstream over a period of time. The study will compare the effects of Ilomedin to a placebo to see if it can help reduce the risk of death within 28 days for patients who are on mechanical ventilation due to this lung condition.

The purpose of the study is to determine if a continuous infusion of Ilomedin at a specific dose can improve survival rates in patients with infectious pulmonary endotheliopathy. Participants in the study will receive the treatment for 72 hours while being closely monitored. The trial will also look at other factors, such as the number of days patients can live without needing additional support like vasopressors, which are medications that help maintain blood pressure, or mechanical ventilation, which is a machine that helps with breathing.

This study is important because it aims to find a potential new treatment option for patients with severe lung infections who require intensive care. By understanding the effects of Ilomedin, researchers hope to improve outcomes for these patients and provide better care in the future. The trial is expected to continue until 2026, with the goal of gathering enough information to make informed conclusions about the treatment’s effectiveness and safety.

]]>